Status:

UNKNOWN

Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

Lead Sponsor:

Sun Yat-sen University

Conditions:

ICC

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

This study were designed to verify the better method of survival for ICC with distant metastasis. Since the traditional method for ICC with distant metastasis. was GEMOX(first-line treatment from NCCN...

Detailed Description

ICC (Intrahepatic CholangioCarcinoma) patients with metastasis has a short survival time and poor prognosis after diagnosis. Treatment methods was few and far from satisfaction. The treatment recommen...

Eligibility Criteria

Inclusion

  • The diagnosis of Intrahepatic CholangioCarcinoma (ICC)
  • With distant metastasis
  • Patients must have at least one tumor lesion that can be accurately measured according to mRECIST criteria.
  • With no previous treatment
  • No Cirrhosis or cirrhotic status of Child-Pugh class A only
  • Not amendable to surgical resection ,local ablative therapy and any other cured treatment
  • The following laboratory parameters:
  • Platelet count ≥ 60,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/ L Serum albumin ≥ 32 g/L ASL and AST ≤ 6 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) \>1,500/mm3

Exclusion

  • Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
  • Known history of HIV
  • History of organ allograft
  • Known or suspected allergy to the investigational agents or any agent given in association with this trial.
  • Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
  • Evidence of bleeding diathesis.
  • Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.

Key Trial Info

Start Date :

February 23 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2021

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04769908

Start Date

February 23 2021

End Date

December 1 2021

Last Update

February 25 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cancer Center Sun Yat-sen University

Guangzhou, Guangdong, China, 510060